Jasper Therapeutics develops briquilimab, a clinical-stage antibody therapy targeting KIT (CD117) for mast cell driven diseases including chronic spontaneous urticaria, chronic inducible urticaria and asthma. Company news centers on briquilimab clinical data from BEACON, open-label extension and ETESIAN studies, financial results and corporate updates, investor conference participation, financing activity and governance changes tied to its development strategy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology firm focused on briquilimab, announced the appointment of Matthew Ford as Vice President of Human Resources. Ford, who has extensive experience in the pharma industry, previously held a senior HR role at Tricida and has worked with Jazz Pharmaceuticals and Gilead Sciences. His appointment aims to strengthen the company’s leadership and support the ongoing development of briquilimab, which targets diseases like chronic spontaneous urticaria and myelodysplastic syndromes. Jasper's briquilimab is in clinical trials, demonstrating safety and efficacy in over 130 subjects related to various conditions, including sickle cell disease and severe combined immunodeficiency.
Jasper Therapeutics (Nasdaq: JSPR) announced the appointment of David Hinds as Senior Vice President of Development Operations on April 10, 2023. Hinds, who has over 25 years of experience in clinical program development, is expected to play a crucial role in advancing briquilimab, an antibody therapy targeting c-Kit (CD117). This therapy aims to treat chronic spontaneous urticaria and lower-risk myelodysplastic syndromes (MDS) while enhancing stem cell transplant conditioning. CEO Ronald Martell expressed confidence in Hinds' ability to lead the clinical development phase effectively, including studies for chronic spontaneous urticaria and MDS. Jasper has demonstrated briquilimab's safety and efficacy in over 130 subjects and aims to further its development in various therapeutic areas.
Jasper Therapeutics, Inc. (NASDAQ: JSPR) announced its participation in the Cantor Fitzgerald The Future of Oncology Virtual Symposium from April 3-5, 2023. Senior Vice President Wendy Pang will join a panel discussion on April 5 at 1:00 PM ET, addressing novel mechanisms for hematological malignancies. Jasper is developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) for conditions like chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS). The therapy has shown promising safety and efficacy in over 130 subjects, with implications for stem cell transplants in rare diseases.
Jasper Therapeutics (Nasdaq: JSPR) has appointed Daniel Adelman, M.D., as its Acting Chief Medical Officer. Adelman brings over 30 years of experience in clinical development, particularly for immunologic diseases, holding leadership roles at companies such as Aimmune and Genentech. CEO Ron Martell expressed enthusiasm about Adelman's addition, citing his expertise as crucial for advancing their novel antibody therapy, briquilimab. This drug targets c-Kit for conditions like chronic spontaneous urticaria and myelodysplastic syndromes. Briquilimab has shown promising efficacy and safety in over 130 subjects, positioning Jasper for potential market success.
Jasper Therapeutics (NASDAQ: JSPR), a biotechnology firm, is focusing on innovative antibody therapies for chronic spontaneous urticaria and myelodysplastic syndromes (MDS). The company announced participation in key conferences in March 2023, including:
- William Blair’s Innovator Series on March 13, featuring CEO Ronald Martell discussing New Therapies in Urticaria.
- Oppenheimer 33rd Annual Healthcare Conference on the same day, where Martell will present the company's corporate updates.
Details for the live webcasts can be found on Jasper's Investor Events page.
Jasper Therapeutics (Nasdaq: JSPR) announced a strategic expansion of its briquilimab development to include chronic spontaneous urticaria. The company raised $101.4 million in net proceeds in January 2023, enhancing its funding for ongoing clinical trials. Fiscal 2022 net loss was $37.7 million, up from $30.6 million in 2021, with R&D expenses rising to $34.6 million from $25.4 million. Jasper presented initial positive clinical data from a Phase I/II trial for sickle cell disease and successful one-year follow-up data for acute myeloid leukemia patients, with 12 out of 12 AML patients achieving donor cell engraftment.